financetom
Business
financetom
/
Business
/
Samsung Elec signs $16.5 billion deal to make chips for global firm
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Samsung Elec signs $16.5 billion deal to make chips for global firm
Jul 27, 2025 6:53 PM

SEOUL (Reuters) - Samsung Electronics ( SSNLF ) said on Monday it has signed a $16.5 billion deal to supply chips for an unidentified major global company, sending its shares up 3.5%.

The South Korean tech giant said the deal signed on Saturday was for contract chip manufacturing and details of the agreement including the counterpart and terms would not be disclosed until the contract is completed at the end of 2033.

The deal comes as Samsung is struggling to compete in the race to make artificial intelligence chips, which has hit its profits and share price.

Samsung has customers like Tesla and Qualcomm for its foundry business, while bigger rival TSMC has customers like Apple and Nvidia.

The deal comes as South Korea is seeking U.S. partnerships in chips and shipbuilding as it is making last-ditch efforts to reach a trade deal to eliminate or cut potential 25% U.S. tariffs.

It is not clear how the order would affect Samsung's plan to start production at its new factory in Texas, which has been delayed as it had struggled to win major customers.

Samsung is grappling to boost production yields of its latest 2-nanometer technology, and the order is unlikely to involve the cutting-edge tech, Lee Min-hee, an analyst at BNK Investment & Securities, said.

Samsung has been losing market share to TSMC in contract manufacturing, underscoring technological challenges the firm faces in mastering advanced chip manufacturing to lure the likes of Apple and Nvidia away from TSMC, analysts said.

($1 = 1,383.6800 won)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Freeport-McMoRan expects lower consolidated sales for copper, gold in third quarter
Freeport-McMoRan expects lower consolidated sales for copper, gold in third quarter
Sep 24, 2025
Sept 24 (Reuters) - Miner Freeport-McMoRan said on Wednesday that it was expecting consolidated sales to be about 4% lower for copper and nearly 6% lower for gold in the third quarter, compared with its prior forecast. (Reporting by Pooja Menon in Bengaluru; Editing by Anil D'Silva) ...
Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell
Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell
Sep 24, 2025
08:11 AM EDT, 09/24/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Wednesday that Australia's Therapeutic Goods Administration approved Leqembi for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease. The approval follows a review process after the regulatory agency initially did not approve the drug in February, the company said. Leqembi targets toxic protofibrils and...
Two US senators urge Tinder parent to act against dating scams on its apps
Two US senators urge Tinder parent to act against dating scams on its apps
Sep 24, 2025
(Reuters) -Two U.S. senators sent a letter to Tinder parent Match on Wednesday, pushing for action against dating scams on the company's platforms and asking for information about its efforts to detect frauds and protect its users. In a letter to Match CEO Spencer Rascoff, Democratic Senator Maggie Hassan and Republican Senator Marsha Blackburn asked the company to provide documents...
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Sep 24, 2025
Sept 24 (Reuters) - Harmony Biosciences ( HRMY ) said on Wednesday its experimental drug for a type of rare genetic disorder failed to meet the main goal in a late-stage trial. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved